Qishen Cuiru Granules Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a granulated multi-component botanical extract intermediate rather than a single isolated molecule. The manufacturer’s model designation for traceability may be represented as QSCG-API-VET-YYMM-XXX, with the exact lot code assigned by the production site. The material is fingerprinted by high-performance liquid chromatography and released with quantification of at least 3 marker constituents per lot. It is manufactured under a quality system aligned with ICH Q7 for active pharmaceutical ingredients and with applicable veterinary GMP provisions. The target particle-size interval for oral solid-dose formulation is a D50 of 180–250 µm, with D10 ≥75 µm and D90 ≤500 µm by laser diffraction according to ISO 13320:2020. Loss on drying is controlled to ≤5.0% using 105°C per Ph. Eur. 2.2.32, and residual granulation solvent is limited under ICH Q3C residual solvent classes. The granulate is packaged in 25 kg polyethylene-lined fibre drums with desiccant when ambient relative humidity exceeds 60%.

Why does the granulated physical form change handling behavior during direct compression and premix blending?

A granulate with controlled particle-size distribution and moderate bulk density tends to flow more uniformly through rotary tablet press feed frames than a spray-dried or micronized botanical powder. Bulk density by Ph. Eur. 2.9.34 is typically controlled at 0.48–0.62 g/cm³, and the Hausner ratio is held between 1.10 and 1.25 by Ph. Eur. 2.9.36. These values indicate sufficient flow for shoe-type feed frames on tablet presses without the use of forced feeders. In low-shear tumble blending with mineral premix carriers, the granulate’s D10 ≥75 µm reduces dust formation and airborne operator exposure relative to micronized powders. The granule structure also lowers segregation potential during discharge because particle-size overlap with carriers such as ground corn or calcium carbonate is closer than that of 10–30 µm fine powders.

On a production-scale ribbon blender of 500 L working capacity, a 10-minute blend time at 25 rpm is generally sufficient to achieve blend uniformity with 1.0% magnesium stearate or 0.5% colloidal silicon dioxide when the granulate is incorporated into directly compressible tablet formulations. Blend uniformity is assessed by sampling 10 locations with acceptance of relative standard deviation ≤5.0% for marker content. For premix manufacture, the granulate is first pre-blended with an equal mass of corn starch or lactose monohydrate before geometric dilution into the full formula. This step mitigates poor distribution of low-inclusion active fractions at 0.1–1.0% w/w. The granulate’s moisture content of ≤5.0% is compatible with conventional tablet film coating and capsule filling environments; higher moisture would increase the risk of punch filming and capsule shell softening.

Release specifications and marker-based standardization

The release specification is built around pharmacopoeial general methods and includes identity, assay, related substances, residual solvents, heavy metals, pesticide residues, and microbial limits. Because the material is a botanical multi-component granulate, marker-based assay is used instead of a single active substance titre. A representative release profile is given in Table 1.

For capsules and oral powders, the granulate is often filled directly into size 0 or size 2 hard gelatin capsules after blending with a low-moisture diluent such as pregelatinized starch or microcrystalline cellulose. The recommended fill weight is calculated from the marker assay and the veterinary dose; no direct substituted weight conversion from single-entity APIs is appropriate because the botanical marker profile varies within pharmacopoeial limits. In a production-scale capsule filler with 10,000 capsules/hour output, hopper segregation of the granulate is reduced by maintaining hopper level above 30% of capacity. For oral powders to be dispersed in drinking water, the granulate is dispersed into a pre-wetted vehicle to avoid floating; use of warm water at 35–40°C under 30-min stirring is typical. Chlorinated drinking water above 2 ppm free chlorine should be avoided because oxidative degradation of botanical phenolics may alter marker content and appearance.

When a medicated premix requires carrier adhesion under high-humidity feed-mill conditions

The granulate’s surface moisture and particle-size distribution affect adhesion to feed carriers during mixing, transport, and bagging. At storage relative humidity above 70%, the granules may soften and release surface moisture, causing particle agglomeration and poor flow through feed-mill micro-dosing systems. In such conditions, the granulate should be used within 24 hours of opening or transferred under dry air with dew point below -10°C. The product is not formulated as a ready-to-feed premix; it is an API intermediate that must be diluted into a licensed premix or compounded preparation by a feed mill or veterinary pharmacist. For carrier selection, porous carriers such as rice hulls or calcium carbonate with bulk density 0.55–0.70 g/cm³ provide better adhesion than nonporous carriers like crystalline sucrose. Segregation can be assessed by sampling 10 points from the mixer and comparing marker content with RSD ≤5.0%.

Parenteral manufacturing routes require more extensive additional processing than oral dosage forms. The as-supplied granulate is not a sterile injectable material. For compounded veterinary injections, the granulate is reconstituted, filtered through a 0.45 µm prefilter and then a 0.22 µm sterilizing-grade membrane, after pH adjustment to a range compatible with marker stability, commonly 5.0–7.0 depending on the extraction profile. Terminal heat sterilization is limited by thermolabile constituents; where steam sterilization at 121°C for 15 min is desired, degradation products must be profiled and controlled. Published data for this specific configuration in injectable solutions is limited, so each processing site must establish solubility, particle shedding, endotoxin recovery, and filter compatibility data. No claim of direct injectable use without additional decontamination and sterility assurance is supported by the supplied granulate.

How do multi-component botanical granules differ from single-entity synthetic APIs in quality control?

Single-entity synthetic APIs are released by assay, related substances, residual solvents, residual catalysts, and crystal form. Multi-component botanical granulates require additional identity and purity tests derived from herbal drug monographs: foreign matter, total ash, acid-insoluble ash, water-soluble extractive, pesticide residues, and aflatoxins where plant material is used. The marker-based HPLC fingerprint is not a direct bioequivalence measure; it is a batch-consistency and authenticity tool. The product may be standardized to ≥3 marker compounds rather than to a single active titre. This creates differences in shelf-life specification: marker variability may be wider, typically 90.0–110.0%, than the 95.0–105.0% often applied to synthetic APIs. Residual solvent management follows ICH Q3C Class 3 limits rather than Class 2 metal catalyst removal. Heavy metal limits are set to veterinary oral and parenteral levels, with lower budgets required when the material feeds injectable or long-duration oral regimens.

The granulate is distinct from simple powdered extracts because it is produced by wet granulation or dry granulation of the extract matrix with a pharmaceutically acceptable binder. This physical form reduces dusting and improves reproducibility of die filling but can introduce additional processing variables such as binder distribution, granule hardness, and fines content. Fines below 75 µm are controlled because excess fines increase cohesion and capsule weight variability. Granule hardness is typically assessed on isolated granules using a texture analyzer; acceptance limits are established per manufacturing site rather than by a pharmacopoeial monograph. In a side-by-side pharmaceutical production campaign, excessive fine material increased tablet weight variability from RSD 1.2% to RSD 3.5% on a high-speed rotary press. This type of batch-to-batch powder-rheology signal is not captured by assay alone and justifies the use of particle-size and flow-property specifications.

Operational incompatibilities that limit direct use in certain dosage forms

The granulate is not compatible with strongly alkaline aqueous solutions above pH 9.0, because phenolic marker degradation and color development accelerate. Avoid combination with strong oxidizing agents, including chlorinated cleaning solutions above 200 ppm within closed equipment, as this may leave residues that degrade botanical polyphenols. For tablet formulations, avoid wet granulation with high-water-content binders if the granulate is already at 5.0% moisture; re-granulation can cause excessive granule growth, increased disintegration time, or compaction defects. For premix use, avoid direct addition to molasses-based liquid feed carriers unless the carrier moisture content is below 15% and the dwell time before consumption is less than 48 hours. The granulate is for further manufacturing use; it is not a finished veterinary product for direct administration. Each manufacturing site is responsible for verifying finished-product stability against the intended dosage form and species.